Navamedic is pleased to announce that it has received final approval for the packaging material in national languages for Norway, Sweden and Denmark, following the earlier announcement on June 27th. Orion Corporation ("Orion"), the product licensor for Finland and the rest of the EU, has also obtained final confirmation for the Finnish market.
"We are excited to have received the last approvals, paving the way for our go-to-market launch in the Nordic region," said Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic.
Flexilev® in OraFID® ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more frequent doses.
OraFID® is a unique, patented, fully mechanical medical device that dispenses precise quantities of minitablets with just a few of twists of the hands.
The launch in the Nordic markets is still anticipated in October 2025.
Source: prnewswire.com
